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INVITED BASIC SCIENCE REVIEW
In 1980, the simple but seminal observation was
made that, when vascular rings of rabbit aorta were
suspended in an organ bath, acetylcholine dilated
the vessels only if the endothelium was intact. This
effect was attributed to a short-lived humoral sub-
stance, which was called endothelium-derived relax-
ing factor. By 1986, it was confirmed that endothe-
lium-derived relaxing factor was identical to nitric
oxide (NO), a free radical gas. What followed was an
explosion of investigative work that culminated in
the awarding of the Nobel Prize in Medicine in
1998 for the discovery of NO as a signaling mole-
cule in the cardiovascular system. In addition to its
key role in cardiovascular physiology, NO is also
important in the nervous system, the immune sys-
tem, the gastrointestinal system, and the pulmonary
system. In view of the almost daily discoveries con-
cerning the critical role of NO in vascular biology, it
is imperative that the vascular surgeon have a basic
understanding of this important molecule.
BIOCHEMISTRY OF NITRIC OXIDE
Unlike most messenger molecules in humans,
which are quite complex, NO is a simple, lipophilic,
free-radical gas with a half life of 3 to 5 seconds.
Because of these unique characteristics, NO is able to
easily diffuse through cell membranes and thus does
not act via membrane receptors. In humans and
other mammals, NO is synthesized from the amino
acid L-arginine by a family of enzymes called NO syn-
thases (NOS). The reaction is a two-step process that
yields the intermediate product, N-hydroxy-L-argi-
nine, and the final products, NO and L-citrulline.
The short half life of NO is the result of its rapid oxi-
dation to nitrite (NO2) and nitrate (NO3) by reac-
tions with O2 and superoxide anion O2–.
Within the vessel wall, the ultimate target of NO
is the enzyme-soluble guanylate cyclase. NO binds
to the heme moiety of this enzyme, which results in
an elevation of the second messenger cyclic guano-
sine monophosphate (cGMP). It is this rise in cGMP
that is responsible for the physiologic actions of NO,
such as vasorelaxation and antiplatelet activity (Fig
1). NO may also modify the activity of several other
enzymes that contain heme or non-heme iron and
thus exhibit different effects. Other indirect actions
of NO result from its interaction with O2 or O2–.
The reaction of NO and oxygen may form N2O3,
which is able to modify thiol groups through S-
nitrosylation to form stable NO carriers that act as
reservoirs of endogenous NO. When NO reacts with
O2–, the powerful oxidant peroxynitrite is formed.
This extremely reactive product is cytotoxic and, in
excessive amounts, may cause tissue injury. Given
the numerous interactions NO may have, its ulti-
mate effect may be beneficial or deleterious.
The NOS enzymes in blood vessels can be broad-
ly categorized into two types: constitutive and
inducible. The constitutive enzyme is always present,
localized to the endothelium and platelets, and pro-
duces the relatively small amounts of NO that are
needed for vascular homeostasis. The stimulation of
the endothelial cell by acetylcholine, bradykinin, sub-
stance P, calcium ionophores, thrombin, serotonin,
and cyclic stress and shear stress results in NO pro-
duction. In contrast, the inducible isoform (iNOS) is
expressed in macrophages, vascular smooth muscle
cells, hepatocytes, and neutrophils only after stimula-
tion with endotoxins or cytokines, such as interferon-
gamma, interleukin-1, and tumor necrosis factor.
Once induced, iNOS produces high concentrations
of NO and is therefore more important in patho-
physiologic states.
PHYSIOLOGY OF NITRIC OXIDE IN THE
VESSEL WALL
The first described and best known action of NO
in the blood vessel is that of vasorelaxation. The NO
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produced by endothelial cells is the major physiologic
regulator of basal blood vessel tone with its continual
release into the circulation. Subsequently, other
important influences of NO on blood elements and
the vessel wall have been described. NO is a potent
platelet inhibitor, also via a cGMP dependent mecha-
nism. In addition, NO inhibits platelet adhesion to
collagen fibrils, endothelial cell matrix, and endothelial
cell monolayers in vitro. Leukocyte adhesion to the
endothelium is also attenuated by NO. Because
platelets and leukocytes accumulated at the site of ves-
sel injury may contribute many of the mediators of vas-
cular smooth muscle cell proliferation, the inhibitory
actions of NO likely play a pivotal role in the modula-
tion of the responses to these mediators (Fig 2).
There is also ample evidence that NO directly
inhibits vascular smooth muscle cell proliferation
and migration and the collagen that comprises the
extracellular matrix in the vessel wall. Taken togeth-
er, it is apparent that NO not only plays a key role in
the maintenance of vasomotor function but that it is
also vitally important in the opposition of thrombo-
sis and vascular lesion formation.
NITRIC OXIDE AND PATHOPHYSIOLOGIC
CONDITIONS
There are a number of pathophysiologic condi-
tions that impact on the capacity of the vessel to pro-
duce NO and result in what has been termed endothe-
lial dysfunction. This endothelial dysfunction may shift
the balance in the vessel wall, which would make it
more vulnerable to vasospasm, thrombosis, and lesion
formation and the resultant clinical consequences (Fig
3). The mechanisms that are potentially responsible for
this decreased production include direct endothelial
cell injury and loss, limitations in substrate availability
(L-arginine), alterations of the NO synthase enzymes,
and increased destruction of NO by superoxide.
Hyperlipidemia and atherosclerosis. It is well
known that many cellular and subcellular events,
such as cell growth and vasomotor function, are
abnormal in atherosclerotic arteries. Given that NO
can interact with a number of the key components in
the formation of atherosclerosis, it is not surprising
that a relationship between NO and atherosclerosis
has been well documented. In humans, hypercholes-
terolemia causes an impairment of endothelial-
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Fig 1. Metabolic pathway of nitric oxide (NO) in blood vessel wall. Endothelial cells secrete
NO in response to variety of external stimuli. NO is released during conversion of L-arginine
to citrulline with NO synthase (NOS). This enzyme is dependent on cofactors flavin adenine
dinucleotide/flavin mononucleotide (FAD/FMN), tetrahydrobiopterin (BH4) calmodulin,
and reduced nicotinamide adenine dinucleotide phosphate (NADPH). After release from
endothelial cell, NO diffuses into extracellular milieu where it can react with smooth muscle
cells or undergo variety of other reactions. cGMP, Cyclic guanosine monophosphate; Ach, ace-
tycholine; ADP, adenosine diphosphate.
dependent vasorelaxation that occurs well before 
any structural changes are seen in the vessel wall.
Interestingly, this endothelial dysfunction is reversed
by the exogenous administration of the NO precur-
sor L-arginine and by lowering cholesterol levels.
Additional support for the protective role of NO in
atherosclerosis is provided by experimental animal
studies that show accelerated plaque formation by
inhibition of NO production.
Hypertension. Hypertension is a well-recog-
nized risk factor in the development of vascular dis-
ease. In patients with hypertension, NO production
is impaired, although the exact mechanism remains
unclear. The diminished vasorelaxation is likely
caused by endothelial rather than smooth muscle cell
dysfunction because the response to nitroprusside (a
NO-producing drug) was identical in patients who
were hypertensive and normotensive.
Diabetes. In diabetes mellitus, there is a gener-
alized vasculopathy that is associated with impaired
NO-dependent vasorelaxation. The mechanism for
this seems to differ between patients with type I and
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Fig 2. Beneficial effects of nitric oxide (NO) on blood vessel wall.
Fig 3. Causes of endothelial dysfunction and their relationship to clinical events.
type II diabetes. In the patient with type I diabetes,
the vasomotor defects are related to vascular smooth
muscle cell resistance to endothelial cell–generated
NO. In the patient with type II diabetes, there
appears to be both endothelial and smooth muscle
cell dysfunction. The endothelial dysfunction is prob-
ably related to the hyperglycemia and the creation of
an osmotic gradient across the endothelial cell wall,
which results in cell swelling and dysfunction. In
addition, glucose metabolism generates an abun-
dance of superoxide anions, which react with NO
and cause its depletion and the production of delete-
rious free radicals. Other conditions that have been
associated with diminished NO production and
endothelial dysfunction include chronic cigarette
smoking and diminished estrogen levels in women.
NITRIC OXIDE AND VASCULAR INTER-
VENTIONS
After endarterectomy, vein bypass grafting, and
balloon angioplasty, there is a denudation of the
endothelium and a stretching of the vessel wall with
damage to the media. This is followed by platelet
adherence and degranulation, with the release of the
potent mitogens platelet–derived growth factor and
fibroblast growth factor. Smooth muscle cell prolif-
eration ensues, with extracellular matrix formation
and collagen deposition. Endothelial repair begins
with the ingrowth of regenerated endothelial cells,
which have an altered morphologic appearance. The
endothelium regenerated after these manipulations
is dysfunctional with respect to NO activity and its
inhibition of vascular smooth muscle cell growth
and vessel thrombosis.
An almost immediate response to endothelial
injury is an increased gene expression of iNOS from
the smooth muscle cells. This is associated with an
increase in NO production, which could represent
an inherent protective mechanism whereby the
injured vessel resists thrombosis and restenosis.
Veins and arteries differ with respect to structure,
function, and NO production. The release of NO
from human saphenous vein is markedly diminished as
compared with the internal mammary artery, possibly
accounting for the inferior patency of coronary vein
grafts as compared with internal mammary grafts. NO
activity in human veins is significantly impaired during
routine intraoperative handling of the grafts before
implantation. Many of the endothelial cells are initial-
ly lost after implantation, which exposes the suben-
dothelium to leukocytes and platelets and makes vein
grafts prone to platelet aggregation and the release of
products that favor vasospasm and thrombosis in the
short term and the development of intimal hyperplasia
in the long term. Furthermore, the NO synthases are
present in human vein grafts and their expression
seems to be a function of the unique environmental
influences that include flow rates and shear stress. 
CONCLUSION
The discovery of NO and its role in physiologic
and pathophysiologic conditions stands as one of the
greatest medical advances of this century. There is
great potential for the treatment of atherosclerosis
and intimal hyperplasia with NO augmentation.
Already, studies in animal models aimed at increas-
ing NO production in vessels with L-arginine admin-
istration, NO donor drugs, and gene transfer of the
NO synthases have been promising. With almost
daily advances in our understanding of this simple
molecule, effective therapeutic strategies in humans
are likely to be just on the horizon.
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